CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.9800
+0.0502 (5.40%)
At close: Oct 7, 2026, 4:00 PM EDT
0.9069
-0.0731 (-7.46%)
After-hours: Oct 7, 2026, 4:08 PM EDT
CytoMed Therapeutics Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.33 | 0.32 | 0.07 | - | - | - |
Other Revenue | 0.46 | 0.54 | 0.43 | 0.51 | 0.36 | 0.11 |
| 0.79 | 0.86 | 0.5 | 0.51 | 0.36 | 0.11 | |
Revenue Growth | 8.11% | 71.02% | -0.86% | 39.52% | 219.67% | 91.43% |
Cost of Revenue | 0.11 | 0.09 | 0.03 | 0 | 0.01 | 0 |
Gross Profit | 0.68 | 0.77 | 0.47 | 0.5 | 0.36 | 0.11 |
Selling, General & Admin | 0.98 | 0.99 | 0.65 | 0.49 | 0.21 | 0.17 |
Research & Development | 2.15 | 2.22 | 1.91 | 1.59 | 1.52 | 1.09 |
Amortization of Goodwill & Intangibles | 0.03 | 0.03 | 0.01 | 0 | 0 | 0 |
Other Operating Expenses | 1.28 | 1.18 | 0.92 | 2.16 | 0.37 | 0.49 |
Operating Expenses | 4.68 | 5 | 3.6 | 4.35 | 2.21 | 1.85 |
Operating Income | -4 | -4.23 | -3.13 | -3.84 | -1.86 | -1.74 |
Interest Expense | -0.02 | -0.02 | -0.02 | -0.05 | -0.13 | -0.12 |
Interest & Investment Income | 0.05 | 0.12 | 0.32 | 0.29 | 0 | 0 |
Earnings From Equity Investments | 0 | -0.01 | 0.01 | -0.03 | -0.03 | -0.21 |
Currency Exchange Gain (Loss) | 0.06 | -0.13 | 0.16 | -0.17 | -0.03 | -0.01 |
Other Non Operating Income (Expenses) | 0.07 | -0.01 | 0.14 | -0.22 | - | - |
EBT Excluding Unusual Items | -3.84 | -4.28 | -2.52 | -4.03 | -2.04 | -2.08 |
Gain (Loss) on Sale of Investments | 0.29 | 0.29 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0 | -0 | - | - | 0 | - |
Asset Writedown | - | -0.01 | - | - | - | - |
Other Unusual Items | - | - | - | -0.1 | -1.09 | 0.02 |
Pretax Income | -3.54 | -4 | -2.52 | -4.13 | -3.13 | -2.05 |
Income Tax Expense | - | - | - | 0 | 0 | - |
Earnings From Continuing Operations | -3.54 | -4 | -2.52 | -4.13 | -3.13 | -2.05 |
Minority Interest in Earnings | 0.04 | 0.02 | 0.01 | 0 | 0 | 0 |
Net Income | -3.51 | -3.98 | -2.52 | -4.13 | -3.13 | -2.05 |
Net Income to Common | -3.51 | -3.98 | -2.52 | -4.13 | -3.13 | -2.05 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 12 | 12 | 12 | 11 | 8 | 7 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 11 | 8 | 7 |
Shares Change | 2.40% | 0.93% | 8.56% | 34.30% | 14.14% | 17.59% |
EPS (Basic) | -0.30 | -0.34 | -0.22 | -0.39 | -0.40 | -0.30 |
EPS (Diluted) | -0.30 | -0.34 | -0.22 | -0.39 | -0.40 | -0.30 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -4.22 | -4.34 | -4.11 | -3.59 | -1.87 | -2.3 |
Free Cash Flow Per Share | -0.36 | -0.37 | -0.36 | -0.34 | -0.24 | -0.33 |
Gross Margin | 85.89% | 89.57% | 93.83% | 99.27% | 97.60% | 96.92% |
Operating Margin | -506.85% | -491.75% | -621.91% | -756.86% | -511.02% | -1528.84% |
Profit Margin | -444.48% | -462.39% | -499.97% | -813.98% | -860.43% | -1802.21% |
Free Cash Flow Margin | -534.90% | -503.61% | -816.52% | -706.96% | -514.47% | -2016.27% |
EBITDA | -3.56 | -3.85 | -2.8 | -3.46 | -1.47 | -1.41 |
D&A For EBITDA | 0.44 | 0.38 | 0.33 | 0.38 | 0.39 | 0.33 |
EBIT | -4 | -4.23 | -3.13 | -3.84 | -1.86 | -1.74 |
Advertising Expenses | - | 0.05 | 0.02 | 0.03 | - | 0 |